AMT-130 Cannot Buy Its Way to a Breakthrough
An anonymous FDA official called AMT-130 a failure. uniQure calls it a disease-modifying breakthrough. The disagreement is not philosophical; it is a direct clash over what Phase 1/2 biomarker data can and cannot tell us. One side is right.
By Dr. Nadia Osei · 3 min read